Heron COO exercises 11,770 RSUs into shares

Heron Therapeutics Chief Operating Officer Mark Earl Hensley reported an automatic RSU conversion into common stock.

Rhea-AI Filing Summary

Heron Therapeutics Chief Operating Officer Mark Earl Hensley reported an automatic RSU conversion into common stock. On April 30, 2026, 11,770 restricted stock units converted into 11,770 shares of common stock at a stated price of $0.00 per share, leaving him with 11,770 common shares directly held.

The derivative section shows 11,770 RSUs converted into common stock and 176,545 restricted stock units remaining after the transaction. A prior grant on January 30, 2026 awarded 188,315 RSUs, scheduled to vest in 16 equal quarterly installments beginning one quarter after the grant date.

Insider Trade Summary

11,770 shares exercised/converted

Exercise 2 txns

Insider Hensley Mark Earl

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	11,770	$0.00	$0.00
Exercise	Common Stock	11,770	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 176,545 contracts (Direct); Common Stock — 11,770 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. F2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Key Figures

Common shares acquired: 11,770 shares RSUs converted: 11,770 units RSUs remaining after transaction: 176,545 units +2 more

5 metrics

Common shares acquired 11,770 shares Common stock from RSU conversion on April 30, 2026

RSUs converted 11,770 units Restricted Stock Units converting into common stock on April 30, 2026

RSUs remaining after transaction 176,545 units Restricted stock units held following April 30, 2026 conversion

RSU grant size 188,315 units RSUs granted on January 30, 2026 with time-based vesting

Vesting installments 16 quarterly installments Time-based vesting schedule beginning one quarter after January 30, 2026

Key Terms

Restricted Stock Units, contingent right, time-based vesting schedule, derivative exercise/conversion

4 terms

Restricted Stock Units financial

"The security title shows "Restricted Stock Units" with 11,770 units converted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

time-based vesting schedule financial

"RSUs vest upon the following time-based vesting schedule in 16 equal quarterly installments"

derivative exercise/conversion financial

"The transaction_action is described as derivative exercise/conversion for the RSUs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Heron Therapeutics (HRTX) COO Mark Earl Hensley report in this Form 4?

Mark Earl Hensley reported the conversion of restricted stock units into common shares. On April 30, 2026, 11,770 RSUs converted into 11,770 shares of Heron Therapeutics common stock, reflecting routine equity compensation activity rather than an open-market stock purchase or sale.

How many Heron Therapeutics shares did the COO acquire in the latest transaction?

The COO acquired 11,770 shares of Heron Therapeutics common stock through RSU conversion. These shares came from restricted stock units that converted at a stated price of $0.00 per share, leaving him with 11,770 common shares directly held after the transaction was completed.

What is the vesting schedule for the 188,315 RSUs granted to HRTX COO Mark Earl Hensley?

The 188,315 RSUs granted on January 30, 2026 vest in 16 equal quarterly installments. Vesting begins one quarter after the grant date, meaning the award releases shares over four years as time-based conditions are met, reflecting a long-term compensation structure tied to continued service.

How many restricted stock units does the Heron Therapeutics COO still hold after this Form 4?

After the reported RSU conversion, the COO holds 176,545 restricted stock units. These RSUs represent contingent rights to receive an equal number of common shares as they vest according to the specified quarterly time-based vesting schedule that began after the January 30, 2026 grant date.

Did the Heron Therapeutics Form 4 for Mark Earl Hensley include any stock sales?

The Form 4 reports no stock sales, only RSU-related acquisitions. It shows 11,770 restricted stock units converting into 11,770 common shares, classified as derivative exercise or conversion, with no transactions coded as open-market sales or other dispositions in the transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 12:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hensley Mark Earl

(Last) (First) (Middle)

100 REGENCY FOREST DRIVE

SUITE 300

(Street)

CARY NORTH CAROLINA 27518

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		M		11,770	A	(1)	11,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	04/30/2026		M			11,770	(2)	(2)	Common Stock	11,770	$0.00	176,545	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

	/s/ Kathryn Lester Attorney-in-Fact for Mark E. Hensley	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)